Associated Papers
Clinical characterization and therapeutic targeting of fusion genes in oncology.
Morand S et al.
Future Oncology (london, England), 2025
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Matrone A et al.
Frontiers in Endocrinology, 2022
Non-small-cell lung cancer: how to manage RET-positive disease.
Andrini E et al.
Drugs in Context, 2022
Precision oncology for RET-related tumors.
Verrienti A et al.
Frontiers in Oncology, 2022
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D et al.
Journal of Medicinal Chemistry, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M et al.
Scientific Reports, 2021
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
Shen T et al.
Npj Precision Oncology, 2021
Drug resistance profiles of mutations in the RET kinase domain.
Liu X et al.
British Journal of Pharmacology, 2018
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Deenen MJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Select a paper to view details